CN101974010A - New compound erigeron breviscapus acid with officinal activity - Google Patents
New compound erigeron breviscapus acid with officinal activity Download PDFInfo
- Publication number
- CN101974010A CN101974010A CN 201010518995 CN201010518995A CN101974010A CN 101974010 A CN101974010 A CN 101974010A CN 201010518995 CN201010518995 CN 201010518995 CN 201010518995 A CN201010518995 A CN 201010518995A CN 101974010 A CN101974010 A CN 101974010A
- Authority
- CN
- China
- Prior art keywords
- acid
- herba erigerontis
- compound
- preparation
- under reduced
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a new compound with structural formula (I) or pharmaceutically acceptable salt thereof. The compound can be obtained by extraction and separation from dry whole plant of Erigeron breviscapus (Vant.)Hand.-Mazz.. The compound has the functions of inflammatory reaction resistance, platelet aggregation resistance, thrombus resistance and vessel expanding and can be used for preparing medicine for treating heart cerebrovascular disease. Formula (I):.
Description
Technical field
The present invention relates to a kind ofly have the new compound of anti-inflammatory response, platelet aggregation-against, antithrombotic and vasodilative effect and acceptable salt pharmaceutically thereof, and contain the medicinal compositions of this compound as the treatment cardiovascular and cerebrovascular diseases of activeconstituents.New compound Herba Erigerontis acid (Brevic acid), preparation method and the application in pharmacy thereof of from Herba Erigerontis, extracting specifically.
Background technology
Up to now, be that the cardiovascular and cerebrovascular diseases sickness rate of representative is high with coronary heart disease, cerebral apoplexy (cerebral apoplexy), its case fatality rate occupies human all kinds of disease death rates first place.Seek new, effectively to treat cardiovascular and cerebrovascular diseases medicament be difficult point and the focus that current pharmacy and clinical medicine circle are paid special attention to.
Herba Erigerontis has another name called Herba Erigerontis, is the dry herb of composite family bitter fleabane platymiscium Erigeron Breviscapus (Vant.) Hand.-Mazz., has expelling cold and relieving exterior syndrome, dispels rheumatism the effect of activating collaterals to relieve pain.The Zhang Renwei of institute of materia medica, Yunnan etc. is separated to flavonoid activeconstituents scutellarin first from Herba Erigerontis, and be scutellarin that mixture main, that contain a small amount of breviscapine (apigenin glycosides) calls Breviscarpine (breviscapin) [Zhang Renwei, Yang Shengyuan, Lin Yongyue, Acta Pharmaceutica Sinica (1981), 16 (1), 68-6].Except scutellarin, patent CN1136434 discloses two coffic acid quininic acid ester compounds 3,5-two caffeoyl quinic acids and 3,4-two caffeoyl quinic acids (3,4-dicaffeoylquimc acid)].CN1064236C then discloses Jiao Meikangsuan (promenonic acid) and bitter fleabane glycosides (erigenoide) is being used aspect the treatment cardiovascular and cerebrovascular diseases.Zhang Weidongs etc. have been applied for activeconstituents 1-(2 '-gamma-pyrone)-6-coffee acyl-β-preparation of D-glucoside and preparation method's the patent CN1252276 that are separated to from Herba Erigerontis.Patent CN1462750 discloses the activeconstituents Erigeroster B that is separated to and preparation method thereof and the application in pharmacy from Herba Erigerontis.In addition, do not see that as yet other new compounds of finding are open in Herba Erigerontis.
Up to now, in Herba Erigerontis, extract, to have a treatment cardiovascular and cerebrovascular diseases active medicine a lot.Wherein major part is the mixture of multiple compound, though these medicines have therapeutic action, multiple composition must cause following problem: the homogeneity of curative effect is poor, quality control difficulty, side effect are difficult to control (injection is especially obvious).The effective medicine of single compounds only has Breviscapine, is difficult to satisfy complicated clinical medicine demand.
In view of as above reason, the inventor is through further investigation, the change platform thing that extraction separation makes new advances from Herba Erigerontis: Herba Erigerontis acid (Brevic acid).It has anti-inflammatory response, platelet aggregation-against, antithrombotic and vasodilation effect through evidence, can be used for preparing the medicine that is used for the treatment of cardiovascular and cerebrovascular diseases.And provide the extraction preparation method of Herba Erigerontis acid.
Summary of the invention
The present invention is directed to the prior art blank, disclose pharmaceutically acceptable salt of new activeconstituents Herba Erigerontis acid (hereinafter to be referred as " The compounds of this invention " or " Herba Erigerontis acid ") or its.The invention provides following technical scheme:
Have following structural formula compound Herba Erigerontis acid:
The The compounds of this invention structured data is as follows:
HRESIMS:m/z 493.1111[M+Na]
+(cal for C
24H
22O
10Na.493.1110), [α]
D 19.6,-138.44 ° (0.06, acetone);
IR (KBr compressing tablet): 3426,2938,1717,1607,1516,1450,1316,1279,1155,1101,1043,1028,835,716cm
-1
UVλmax(MeOH)：228.5(22174)，315(20224)nm；
1H?NMR(400MHz，DMSO-d6，ppm)：2.28-2.48(2H，m，H-2α，H-2β)，3.95，4.18(each?1H，m，H-9)，4.15(1H，m，H-6)，4.59(1H，t，J＝5.6Hz，H-5)，5.31(1H，t，J＝5.2Hz，H-4)，5.64(1H，t，J＝5.6Hz，H-3)，6.21(1H，d，J＝16Hz，H-3”)，6.74(2H，d，J＝7.6Hz，H-6”，H-8”)，7.29(2H，d，J＝7.6Hz，H-5”，H-9”)，7.35(1H，d，J＝16Hz，H-2”)，7.54(2H，m，H-4’，H-6’)，7.65(1H，m，H-5’)，8.01(2H，m，H-3’，H-7’)。
13C?NMR(100MHz，DMSO-d6，ppm)：104.0(C-1)，38.3(C-2)，66.0(C-3)，67.8(C-4)，74.1(C-5)，82.3(C-6)，59.4(C-9)，167.2(C-10)，165.8(C-1’)，130.2(C-2’)，129.9(C-3’，C-7’)，129.3(C-4’，C-6’)，133.9(C-5’)，165.5(C-1”)，145.9(C-2”)，113.7(C-3”)，125.1(C-4”)，130.7(C-5”，C-9”)，116.3(C-6”，C-8”)，160.6(C-7”)。
This compound is a new compound, and is identical with disclosed Erigeroster B skeleton among the patent CN1462750, but substituting group and position are all different.Erigeroster B is to form the coffic acid acid esters at 3,5 respectively, the Herba Erigerontis acid that this patent relates to then 3 go up to replace and form benzoic ether by benzoyl, then form the p-Coumaric Acid ester on 4.
The said salt of the present invention is meant pharmacy acceptable salt, for example with sodium hydroxide, and the salt that alkali such as potassium hydroxide form.
Pharmaceutically acceptable carrier of the present invention is meant the pharmaceutical carrier of pharmaceutical field routine, for example: thinner, vehicle such as water etc., weighting agent such as starch, sucrose etc.; Tamanori such as derivatived cellulose, alginate, gelatin and polyvinylpyrrolidone; Wetting agent such as glycerine; Disintegrating agent such as agar, lime carbonate and sodium bicarbonate; Absorption enhancer such as quaternary ammonium compound; Tensio-active agent such as cetyl alcohol; Absorption carrier such as kaolin and soap clay; Lubricant such as talcum powder, calcium stearate and magnesium and polyoxyethylene glycol etc.Can also in composition, add other assistant agents such as flavouring agent, sweeting agent etc. in addition.
The invention provides the method for the The compounds of this invention of preparation claim 1: get the herb or the over-ground part of Herba Erigerontis, pulverize, extract three times, merge No. three times extracting solution, concentrating under reduced pressure with 0-95% alcohol or 0-95% aqueous acetone solution.Concentrated solution polyamide resin chromatography, first water wash-out is used the ethanol elution of 50-90% again, collects concentrating under reduced pressure behind the 50-90% ethanol eluate.This partial concentration liquid can separate with the following method at least and prepares Herba Erigerontis acid:
1, with silica gel chromatography repeatedly;
2, with increasing/reduce pressure the preparation of anti-phase (Rp-18) column chromatography;
3, with dextrane gel (Sephadex LH-20) purifying preparation repeatedly;
4, with above-mentioned 1 in conjunction with the preparation of 2 and/or 3 method.
Remove above-mentioned preparation method, certain methods well known to those skilled in the art also can be used to prepare Herba Erigerontis acid, distributes extraction back with various just anti-phase chromatography methods to prepare The compounds of this invention with ethyl acetate extraction, concentrated solution with solvent such as aforementioned Herba Erigerontis herb.
Pharmacodynamics test research
One. the pharmacological action for the treatment of cardiac and cerebral vascular diseases
1. to the influence of different inductor induced platelet aggregations
1.1 material
Herba Erigerontis acid: 20mg/kg irritates stomach;
Blank group: physiological saline;
Positive control: acetylsalicylic acid.
1.2 experimental technique
Cavy grouping (8 every group) was irritated stomach 5 days, blank physiological saline.Last administration rear neck artery blood sampling in 1 hour, with the Sodium Citrate anti-freezing, mixing, centrifugal, merge supernatant liquor as PRP (platelet rich plasma), platelet count; Remaining blood plasma is centrifugal, gets supernatant liquor as PPP (platelet poor plasma); With the PPP zeroing, to get PRP300 μ l and add opacity tube, 37 ℃ of incubations add inductor PAF (platelet activation factor), assemble different time, record data.The results are shown in Table 1.
Compare * * p＜0.01 with the blank group
Test structure and above-mentioned experimental result with the ADP inductor are similar.
By The above results as can be known, Herba Erigerontis acid can suppress different inductor inductive platelet aggregations (aggegation), reduce MA, and effect and acetylsalicylic acid are similar.
2. to the thrombotic influence of rats in vitro
Take off according to the pharmacology known method and to measure the thrombus temperature respectively and heavily reach the thrombus dry weight.
The result shows, in rat artery-thrombotic experiment of venous blood flow coronary artery bypass grafting, compares Herba Erigerontis acid group P＜0.01 with model control group; In rats in vitro thrombosis process, Herba Erigerontis acid makes wet weight of thrombus than control group significant difference (P＜0.01) be arranged relatively.
Two. the pharmacological action of anti-inflammatory aspect: p-Xylol causes the influence of mouse skin capillary permeability
The compounds of this invention thing: 20mg/kg irritates stomach;
Control group: physiological saline;
Experimental technique
" herbal pharmacology research methodology " with reference to the Qi Chen chief editor makes the animal inflammatory model, the results are shown in following table:
Compare * * P＜0.01 with control group
Three. the vasoactive test
The influence (n=10) that the acid of table 2. Herba Erigerontis induces rabbit aorta to shrink to phyenlephrinium
Contrast before * P＜0.01vs administration
Acid has above pharmacologically active in view of Herba Erigerontis, and therefore envisioning Herba Erigerontis acid can be used for treating cardiovascular and cerebrovascular diseases, especially coronary heart disease, cerebral apoplexy (apoplexy).
The compounds of this invention can be separately or is made oral dosage forms such as tablet, capsule, dripping pill, granule or injection liquid, injectable dosage forms such as freeze-dried with the auxiliary material of other medicinal permission by prior art.
Embodiment
Embodiment 1: the extracting and preparing technique of Herba Erigerontis acid
Get the herb 10kg of Herba Erigerontis, pulverize, extract three times, merge No. three times extracting solution, concentrating under reduced pressure with 70% aqueous acetone solution.Polyamide resin chromatography on the concentrated solution, first water wash-out is used 60% ethanol elution again, collects back concentrating under reduced pressure behind 60% ethanol eluate, and this part prepares Herba Erigerontis acid (Brevic acid) 50g with silica gel chromatography repeatedly.
Embodiment 2: the extracting and preparing technique of Herba Erigerontis acid
Get the herb 10kg of Herba Erigerontis, pulverize, extract three times, merge No. three times extracting solution, concentrating under reduced pressure with 70% aqueous ethanolic solution.Polyamide resin chromatography on the concentrated solution, first water wash-out is used 80% ethanol elution again, collects back concentrating under reduced pressure behind 80% ethanol eluate, and this part prepares Herba Erigerontis acid (Brevic acid) 60g with supercharging anti-phase (Rp-18) column chromatography for separation.
Embodiment 3: the extracting and preparing technique of Herba Erigerontis acid
Get the herb 10kg of Herba Erigerontis, pulverize, use extraction with aqueous solution three times, merge No. three times extracting solution, concentrating under reduced pressure.Polyamide resin chromatography on the concentrated solution, elder generation's water wash-out, use 50% ethanol elution again, collect back concentrating under reduced pressure behind 50% ethanol eluate, this part with dextrane gel (Sephadex LH-20) repeatedly purifying prepare Herba Erigerontis acid (Brevic acid) 40g.
The preparation technology of the tablet of embodiment 4, Herba Erigerontis acid
After Herba Erigerontis acid 10g mixed with starch, add 10% starch slurry 10g and make softwood, cross 14 mesh sieves and granulate, dry under 70-80 ℃ of temperature, cross the whole grain of 12 mesh sieves, add Magnesium Stearate 2g mixing after, be pressed into 1000, promptly.Every contains Herba Erigerontis acid 10mg.
The capsule preparation technology of embodiment 5, Herba Erigerontis acid
Add the acid of 10g Herba Erigerontis, after adding 80 ℃ of exsiccant starch 30g and stearyl ester magnesium 2g and mixing, be distributed into 1000 capsules, every capsules contains Herba Erigerontis acid 10mg.
The injection liquid preparation of embodiment 6. Herba Erigerontis acid
The acid of 10g Herba Erigerontis is dissolved in the cold distilled water for injection of 5000ml, and 85g sodium-chlor, 2g sodium hydroxide mixed dissolution are in the distilled water for injection of 1000ml heat.Two kinds of solution are mixed, add water to 10000ml, adjusting pH value is filtered at the 5.0-7.0 filter stick, and membrane filtration adds nitrogen envelope bottle after clarity test is qualified, and at 115 ℃, 10atm pressure was sterilized 25 minutes down.
The freeze-dried preparation of injection of embodiment 7. Herba Erigerontis acid
Get an amount of potassium hydroxide, sodium-chlor, N.F,USP MANNITOL, add 1600 milliliters of dissolvings of injection water, add gac 3.2g, absorb 30 minutes depyrogenations, remove by filter activated carbon, add Herba Erigerontis acid 10g in filtrate, regulating pH is 6.0～7.3, and millipore filtration filters, add the injection water to 2000ml, be packed as 1000, lyophilize, promptly.
Claims (4)
1. have pharmaceutically acceptable salt of the acid of following structural formula compound Herba Erigerontis or its:
2. preparation method who prepares the compound of claim 1 is characterized in that getting the herb or the over-ground part of Herba Erigerontis, pulverizes, and extracts three times with 0-95% ethanol or 0-95% aqueous acetone solution, merges No. three times extracting solution, concentrating under reduced pressure.Concentrated solution polyamide resin chromatography, elder generation's water wash-out, use the ethanol elution of 50-90% again, concentrating under reduced pressure behind the collection 50-90% ethanol eluate, this part is with silica gel chromatography repeatedly, and/or, prepare Herba Erigerontis acid in conjunction with increasing/reduce pressure anti-phase (Rp-18) column chromatography, Scphadex LH-20 purifying repeatedly.
3. pharmaceutical composition, its compound that contains claim 1 is as activeconstituents and pharmaceutically acceptable carrier.
4. the application of the compound of claim 1 in the medicine of preparation treatment cardiovascular and cerebrovascular diseases.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105189952A CN101974010B (en) | 2010-10-26 | 2010-10-26 | New compound erigeron breviscapus acid with officinal activity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105189952A CN101974010B (en) | 2010-10-26 | 2010-10-26 | New compound erigeron breviscapus acid with officinal activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101974010A true CN101974010A (en) | 2011-02-16 |
| CN101974010B CN101974010B (en) | 2012-01-04 |
Family
ID=43573927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010105189952A Active CN101974010B (en) | 2010-10-26 | 2010-10-26 | New compound erigeron breviscapus acid with officinal activity |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101974010B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102351874A (en) * | 2011-08-24 | 2012-02-15 | 云南生物谷灯盏花药业有限公司 | New erigeroster compound with medicinal activity |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1462750A (en) * | 2003-04-22 | 2003-12-24 | 中国科学院昆明植物研究所 | Erigeron ester B and its preparation method as well as application in pharmacy |
-
2010
- 2010-10-26 CN CN2010105189952A patent/CN101974010B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1462750A (en) * | 2003-04-22 | 2003-12-24 | 中国科学院昆明植物研究所 | Erigeron ester B and its preparation method as well as application in pharmacy |
Non-Patent Citations (2)
| Title |
|---|
| 《天津药学》 20030430 吕曙华 等 灯盏细辛的研究进展 第46-48页 1-4 第15卷, 第2期 2 * |
| 《河北中医药学报》 20091231 谷党英 灯盏细辛的研究进展及临床应用 第48-49页 1-4 第24卷, 第2期 2 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102351874A (en) * | 2011-08-24 | 2012-02-15 | 云南生物谷灯盏花药业有限公司 | New erigeroster compound with medicinal activity |
| CN102351874B (en) * | 2011-08-24 | 2013-09-11 | 云南生物谷药业股份有限公司 | New erigeroster compound with medicinal activity |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101974010B (en) | 2012-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100540012C (en) | A kind of Radix Bupleuri extract, its preparation method and application thereof | |
| EP2520305B1 (en) | Pharmaceutical composition including sunflower extract, preparative method and use thereof | |
| WO2006034655A1 (en) | Steroidal saponin pharmaceutical composition, its preparation method and use | |
| CN101791314B (en) | Application of crocin in preparing hypnotic drug | |
| CN1931236B (en) | Medicine composition of red sage and rhodiola root | |
| CN107412430A (en) | A kind of radix scrophulariae water extract and its application | |
| CN103006838A (en) | Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases | |
| CN101974011B (en) | New compound methyl brevicate with medical activity | |
| CN104352624B (en) | Application of the anaesthetic core fragrant plant n-butanol extract in preventing and treating diabetes medicament is prepared | |
| JP2004518751A (en) | Method for producing Liangtoujian extract, pharmaceutical composition containing the extract and use thereof | |
| CN103006769A (en) | Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN102274260A (en) | Medicinal composition of notoginseng root extract and preparation method thereof | |
| CN101974012B (en) | Novel compound ethyl brevicate with pharmaceutical activity | |
| CN101874841A (en) | Total glycosides extractive of morinda plants, as well as preparation method and application thereof | |
| CN101428050B (en) | Active composition for treating thrombus, cardio-cerebrovascular system diseases | |
| CN100509009C (en) | A Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and ischemic apoplexy, and its preparation method | |
| CN101974010B (en) | New compound erigeron breviscapus acid with officinal activity | |
| CN102370901A (en) | Pharmaceutical composition for treating nephrosis and preparing process thereof | |
| CN102351874B (en) | New erigeroster compound with medicinal activity | |
| CN113069516B (en) | Traditional Chinese medicine compound composition for preventing and treating cutaneous pruritus and application thereof | |
| CN1994277B (en) | Solid preparation of salvianolic acid A of red sage root and preparation process thereof | |
| CN102716231B (en) | A kind of Chinese medicine composition and application thereof for the treatment of brain injury and cerebral edema | |
| CN102018740B (en) | Medicinal composition containing extracts of leaves of helianthus and application of the same | |
| CN1923191B (en) | Use of flavanone kind composition in preparation of medicine for curing cardio vascular diseases | |
| CN104435105B (en) | One kind is by Radix Astragali, Radix Salviae Miltiorrhizae, Radix Notoginseng, the pharmaceutical composition of dalbergia wood preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: YUNNAN BIOVALLEY PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: YUNNAN BIOLOGICAL VALLEY BREVISCAPIN PHARMACEUTICAL CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 650224 Yunnan Province, Kunming Beijiao Palace Patentee after: YUNNAN BIOVALLEY PHARMACEUTICAL CO., LTD. Address before: 650224 Yunnan Province, Kunming Beijiao Palace Patentee before: Yunnan Biovalley Dengzhanhua Pharmaceutical Co., Ltd. |